Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acutus Names David Roman As New CEO; Mickelsen Departs Company

Executive Summary

After announcing that its estimated second-quarter 2022 revenue exceeded analysts’ expectations, Acutus announced that David Roman, the interim CEO and CFO, is now the permanent CEO. Also, Steven Mickelsen announced that he is stepping down as Acutus’ chief translational science officer.

You may also be interested in...



Minute Insight: Acutus Adds Another Device To The Left-Heart Business It Sold To Medtronic

The company announced the US launch of the AcQCross Qx transseptal dilator/needle. It is specifically designed to help deploy Boston Scientific’s Watchman left-atrial appendage closure device, but it is part of the left-heart access device portfolio that Acutus recently sold to Medtronic.

Acutus Sells Left-Heart Access Business To Medtronic; Extends Its Cash Runway

The deal, potentially worth more than $85m, will allow Acutus to get more revenue from its core AcQMap electrophysiology mapping technology and invest in the development of its pulsed field ablation system.

Acutus Builds On Arrhythmia Mapping Success With New Ablation Devices

The company is supporting two US trials of the AcQBlate Force ablation catheter to support FDA approval of the system to treat atrial flutter and atrial fibrillation.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel